Tenon Medical
TNON
7 hedge funds and large institutions have $536K invested in Tenon Medical in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more ownership
Funds ownership: 0.08% → 0.08% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
40% less capital invested
Capital invested by funds: $888K → $536K (-$352K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.49K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.45K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$349 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$349 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LF
Lee Financial
Dallas,
Texas
|
-$5.53K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$158 |
TNON Hedge Fund Activity: Q1 2024 in Review
7 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Tenon Medical (TNON) for Q1 2024, worth a combined $536K — down 40% from $888K a quarter earlier.
Fund positioning in TNON was balanced in Q1 2024: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $3.49K. The largest seller was Lee Financial, exiting entirely with an estimated $5.53K sold.
- 7 institutional investors held Tenon Medical (TNON) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $536K of Tenon Medical stock for Q1 2024, down 40% quarter-over-quarter.
- 1 fund opened new Tenon Medical positions in Q1 2024 and 1 closed out, a net change of 0 holders.
- The largest Tenon Medical buyer in Q1 2024 was Tower Research Capital (TRC), an estimated $3.49K added.
- The largest Tenon Medical seller in Q1 2024 was Lee Financial, an estimated $5.53K sold.
Based on aggregated 13F filings for Q1 2024.